Anno Borkowsky appointed to the LANXESS Board of Management

Taking charge of Specialty Additives segment Reorganization of the Additives business units  Cologne, June 11, 2019: The Supervisory Board of LANXESS AG has appointed...

IT & Software Support

Financial Results

Product News


Dr. Reddy’s Laboratories announces entering into a definitive agreement to sell its neurology branded...

Hyderabad, June 14, 2019: Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announces that it has entered into a definitive asset purchase...

Clinical Trails

Phase III DECISION Trial of Nexavar® (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival...

Berlin, January 3, 2013 – Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase III trial of Nexavar® (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement in progression-free survival. The study, called DECISION, evaluated the efficacy and safety of Nexavar compared to placebo. The safety and tolerability were generally consistent with the known profile of Nexavar. Detailed efficacy and safety analysis from this study are expected to be presented at an upcoming medical meeting. Effective treatment options are urgently needed for patients with RAI-refractory differentiated thyroid cancer,” said Dimitris Voliotis, MD, Vice President, Global Clinical Development Oncology, Bayer HealthCare. “We are pleased that the results of this study demonstrate that Nexavar may provide a treatment option for these patients.

Media Partner


Health Care

Alternative Medicine

Eye Care



- Advertisement -



Latest News

Dental Care

Hospital Management

Drug Discovery & Development




Our Partners



Machinery & Equipments

Featured On